Table 2.
Summary of AEs in the total study population
| AEs, n (%) | Pembrolizumab + dinaciclib | |||
|---|---|---|---|---|
| rrCLL, n = 17 | rrDLBC, n = 38 | rrMM, n = 17 | All disease cohorts, N = 72 | |
| None | 0 (0.0) | 1 (2.6) | 1 (5.9) | 2 (2.8) |
| At least 1, any grade | 17 (100) | 37 (97.4) | 16 (94.1) | 70 (97.2) |
| Grade 3-4 | 13 (76.5) | 28 (73.7) | 10 (58.8) | 51 (70.8) |
| Grade 5 | 1 (5.9) | 2 (5.3) | 0 (0.0) | 3 (4.2) |
| Serious | 13 (76.5) | 17 (44.7) | 6 (35.3) | 36 (50.0) |
| TRAE, any grade | 13 (76.5) | 25 (65.8) | 8 (47.1) | 46 (63.9) |
| Grade 3-4 | 9 (52.9) | 13 (34.2) | 6 (35.3) | 28 (38.9) |
| Grade 5 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Serious | 5 (29.4) | 5 (13.2) | 2 (11.8) | 12 (16.7) |
| Any AE leading to discontinuation of any study drug | 4 (23.5) | 0 (0.0) | 2 (11.8) | 6 (8.3) |
| Any TRAE leading to discontinuation of any study drug | 1 (5.9) | 0 (0.0) | 2 (11.8) | 3 (4.2) |
Nonserious AEs up to 30 days after last dose and serious AEs up to 90 days after last dose are included.
TRAE, treatment-related adverse event.